Pelthos Therapeutics Inc.

AMEX:PTHS

Biotechnology

Healthcare
$16.54 -1.28%

-$0.37 today

Market cap
$63.32M
Beta
3.13
P/E (TTM)
-0.7
EPS (TTM)
-$15.58
52W Low $16.50High $37.50

Volume 0.01M

Average 0.04M

PTHS Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Pelthos Therapeutics Inc.AMEX: PTHS

Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026

Change in working capital turns negative

Q1 FY2026 change in working capital was -$2.44M, compared with $755.44K a year earlier. Trailing-twelve-month change in working capital was -$9.26M.

Context

  • Change in working capital amounted to 36.1% of revenue in FY2025.
  • Change in working capital increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly change in working capital holds near -$2.44M or moves back toward the trailing-twelve-month quarterly average of -$2.32M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$2.44M-42.3% QoQ
Last fiscal yearDec 2025
-$6.07M-17630.5% YoY
LTMMar 2026
-$9.26M-928.5% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-422.3%——
1 year-17630.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
(6.07M) USD
Year-over-year change
-17630.5%

Change in Working Capital vs competitors

How PTHS compares with its peers on the latest reported figures

  • PTHS's LTM Mar 2026 change in working capital of $9.26M is the largest of the 4 companies compared; the peer median is $865.81K.
  • Its year-over-year change of -928.5% is the lowest of 4, against a peer median of +874.2%.
  • Change in working capital amounts to 33.4% of revenue for PTHS.
PTHS Competitors Peer median
Change in Working Capital for PTHS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PTHSPelthos Therapeutics Inc.LTM Mar 2026$9.26M -928.5%—33.4%
CINGCingulate Inc.LTM Mar 2026$1.49M +1007.7%+11.5%—
ENLVEnlivex Therapeutics Ltd.LTM Dec 2025$865.81K +170.7%+0.5%—
LIXTLixte Biotechnology Holdings, Inc.LTM Mar 2026$269.66K +874.2%+38.7%—
Peer median (excluding PTHS) $865.81K+874.2%+11.5%—

Competitors are the stored peer set for PTHS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(2.46M)(7.38M)(7.96M)(43.32M)
Depreciation & Amortization0002.36M
Deferred Income Tax0000
Stock-Based Compensation110.15K1.73M1.8M0
Change in Working Capital640.86K2.05M34.63K(6.07M)
Accounts Receivables00(45.79K)(8.81M)
Inventory0001.78M
Accounts Payables413.6K1.63M1.18M1.36M
Other Working Capital227.26K424.07K(1.1M)(395K)
Other Non-Cash Items140.43K2.62M328.93K24.44M
Operating Cash Flow(1.57M)(981.03K)(5.79M)(22.59M)
Capital Expenditures000(99K)
Acquisitions (Net)000(5.14M)
Purchases of Investments0000
Sales of Investments0000
Other Investing Activities0000
Investing Cash Flow000(5.24M)
Debt Repayment400K766.94K321.43K17.75M
Common Stock Issued0255.41K6.05M27.59M
Common Stock Repurchased00(166.51K)0
Dividends Paid0000
Other Financing Activities1.22M000
Financing Cash Flow1.62M1.02M6.21M45.34M
Effect of Forex Changes000(443)
Net Change in Cash55.07K41.32K417.05K17.51M
Free Cash Flow(1.57M)(981.03K)(5.79M)(22.69M)

Pelthos Therapeutics Inc.

AMEX:PTHS

Intrinsic Alpha fair value

Locked

Current Price

$16.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.